Guggenheim analyst Subbu Nambi noted that Grail (GRAL) announced a partnership yesterday with Quest Diagnostics (DGX) to offer Galleri, Grail’s multi-cancer early detection, or MCED, test. The firm, which views this distribution partnership as a positive for Grail as it simplifies the ordering process and leverages Quest’s network and infrastructure to make Galleri more accessible to U.S. patients, keeps a Neutral rating on Grail shares.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.